AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI).

Conducted across multiple centers in India, TUXEDO-2 randomized approximately 1800 patients to recieve either ticagrelor or prasugrel in combination with aspirin. The primary endpoint was a composite of death, non-fatal myocardial infarction, stroke and major bleeding.

The study found that in patients with multivessel disease undergoing PCI, ticagrelor did not meet non-inferiority compared to prasugrel when added to aspirin as part of dual antiplatelet therapy. 
 

For more content from AHA 2025 head to the Late-breaking Science Video Collection.

Recorded on-site at AHA Scientific Sessions 2025, New Orleans.

Editor: Mirjam Boros, Jordan Rance
Videographer: Mike Knight, Dan Brent

Support: This is an independent interview produced by Radcliffe Cardiology.